key: cord-0917169-i7yzofka
authors: Torres-Machorro, Adriana; Anguiano-Álvarez, Victor Manuel; Grimaldo-Gómez, Flavio Adrian; Rodríguez-Zanella, Hugo; de la Rosa, Evelyn Cortina; Mora-Canela, Sergio; Lerma, Claudia; García-Cruz, Edgar; Ramos-Enriquez, Ángel; Ramirez-Marroquin, Samuel; Izaguirre-Ávila, Raúl; Rojas-Velasco, Gustavo
title: Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
date: 2020-09-01
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.08.043
sha: 2d9ada74843dc5c782ae13688bcf76bc10bace41
doc_id: 917169
cord_uid: i7yzofka

• Clinical signs are not useful for detecting DVT in critically ill COVID-19 patients; • DVT occurs despite full dose anticoagulation in critically ill COVID-19 patients; • Severe COVID-19 patients present a high prevalence of bilateral DVT.

Patients with severe COVID-19 pneumonia might experience a high cumulative incidence of thrombotic complications [1] , due to coagulopathy, excessive inflammation, and vascular endothelial dysfunction [2] . Data regarding the incidence of deep vein thrombosis (DVT) in this patient subset, without clinical signs of venous thromboembolism (VTE), has not been deeply analyzed even though these patients are at higher risk of death [3] .

Furthermore, thrombotic complications have been found in up to 31% of patients in the intensive care unit (ICU) despite systematic thromboprophylaxis [4, 5] . A recent report has also addressed the incidence of asymptomatic DVT in hospitalized patients with COVID- was systematically performed for anticoagulation monitoring and adjustment in obese patients (n =12) and those with acute renal failure (n = 20) [8] . Platelet activity was also monitored in those found to have DVT despite therapeutic anti-factor-Xa activity, with Multiplate ® due to its possible role when interacting with endothelial cells in the development of thrombosis and micro thrombosis in organs and tissues other than lungs [9] .

Among the 30 evaluated patients, 30% developed asymptomatic DVT (Table 1) . J o u r n a l P r e -p r o o f Both groups presented with lymphopenia and a highly inflammatory, prothrombotic state without coagulopathy (Table 1) . Although the D-dimer was elevated above 0.240 μg/mL in all patients with DVT and 95% of patients without DVT, the median values of D-Dimer were higher in the DVT group compared to the group without DVT (Table 1) , abrupt increases in D-Dimer were no different between groups (Table 2) .

Every patient in the DVT group and 86% of the non-DVT group received full-dose anticoagulation (p=0.534). The remaining 14% received high-prophylactic doses. Most patients were treated with Enoxaparin (Table 1) . Notably, DVT occurred despite therapeutic levels of anti-Xa activity in patients receiving LMWH and optimal PTT in a patient with chronic renal failure on a continuous unfractionated heparin IV infusion ( Table   2) . All DVT patients were tested for platelet function using a commercially available ^ Patient also presented left proximal DVT */ Measurement was not possible due to rapid patient deterioration and death. +Patient already under acetylsalicylic acid. **Patients 2 and 4 had initial doses of anticoagulant therapy and control after dose titration. Patient 2 was already under therapeutic levels, but dose adjustment was decided by consensus. ¨Therapeutic levels are considered between 0.4UI/mL-1UI/mL ^^Patient 9 achieved therapeutic levels of anti-Xa activity 72 hours after UFH infusion placement. 'Analysis performed after ASA was initiated according to DVT findings. The latter was maintained due to normal platelet function demonstrated with ASA therapy. Unexpectedly, thrombosis was frequently found in both legs, even though VTE's classics are usually unilateral. Highly elevated D-Dimer value was the only factor associated with DVT. Moreover, abrupt changes proposed to increase VTE risk in COVID-19 patients were similar in both groups. We also observed that DVT, despite therapeutic anticoagulation, is common in critical patients with severe SARS-Cov-2 pneumonia.

Resulting in substantially higher thrombotic events than other critically ill patients, that may require a more aggressive anticoagulation scheme.

The mechanisms contributing to DVT in fully anticoagulated patients and the laboratory and clinical factors associated remain unclear. Tropism of this coronavirus to endothelial tissue, secondary to high expression of angiotensin-converting enzyme 2, may play a role in the thrombosis pathogenesis of these optimally anticoagulated patients [9, 12] .

Thus, direct endothelial damage may intervene. As long as the thrombotic mechanism remains imprecise, in highly inflammatory prothrombotic scenarios such as SARS-Cov-2, timely immune modulation with cell-mediated and humoral strategies to avoid the COVID-19 cytokine storm syndrome and the associated complications should be considered, along with the measurement of other pro-inflammatory markers [13] .

Clinical examination has low accuracy for diagnosing DVT in fully anticoagulated critically ill COVID-19 patients. Compression ultrasound is a useful screening tool in this J o u r n a l P r e -p r o o f asymptomatic group of patients to identify DVT and potentially prevent pulmonary embolism, already known to increase mortality rates. Highly elevated D-Dimer levels are associated with DVT findings. Our results show that thrombosis occurs despite therapeutic levels of anti-Factor-Xa activity. Whether these findings suggest that full-dose anticoagulation may not be enough in this subset of patients requires further investigation.

Anticoagulation monitoring and aggregometry in selected cases may be beneficial in severe COVID-19. The clinical significance of asymptomatic DVT in patients with severe SARS-Cov-2 pneumonia and the mechanisms involved in these thrombotic events occurring under optimal anticoagulation warrant further study.

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome

Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge

Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis

Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease

Evaluation of aspirin response by Multiplate® whole blood aggregometry and light transmission J o u r n a l P r e -p r o o f aggregometry

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

Targeting the immunology of coronavirus disease-19: synchronization creates symphony

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity

We would like to thank Karen Guadalupe Cortés Cortés and Maria Oliva Romero Arroyo for their assistance in performing coagulation and platelet function laboratory testing.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that they have no conflict of interest.J o u r n a l P r e -p r o o f